Does Hypoattenuated Leaflet Thickening After TAVR Matter?

A 3-year follow-up study suggests an adverse effect on valve function but no increase in mortality or stroke incidence.

Hypoattenuated leaflet thickening (HALT), diagnosed by computed tomography (CT) scan, is observed in up to 10% of patients after transcatheter aortic valve replacement (TAVR) and may be associated with cerebrovascular events and hemodynamic valve dysfunction. However, it is most often asymptomatic and can resolve spontaneously. For these reasons, data are needed on its longer-term clinical significance.

In a single-center study, investigators examined 3-year outcomes in 804 patients who had undergone TAVR (most receiving balloon-expandable valves), among whom 115 (16%) received a diagnosis of early HALT. Patients who received planned oral anticoagulation were excluded from the analysis. No baseline or procedural characteristics significantly…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)